Editorial disclosure: This article is original educational commentary based on the cited literature. It summarizes and interprets published evidence rather than reproducing source text. Clinical decisions should be based on the full original publications, current guidelines, regulatory status, and individual patient factors.
Why the update matters
Anemia remains one of the most common complications of chronic kidney disease, but its management has become considerably more nuanced. Iron deficiency, inflammation, reduced erythropoietin production, blood loss, nutritional deficiencies and treatment-related factors may coexist in the same patient. The 2026 KDIGO guideline updates the previous 2012 guidance and incorporates more than a decade of new evidence.
A practical four-step framework
A useful approach is to confirm and characterize anemia, identify reversible causes, assess iron availability and replacement needs, and decide whether erythropoiesis-stimulating therapy or another pharmacologic strategy is appropriate.
Hemoglobin is not the only outcome that matters. Decisions must balance symptoms and quality of life against cardiovascular and thrombotic risks, treatment burden, iron-related concerns, transfusion exposure and possible sensitization in patients who may ultimately undergo transplantation.
Iron, ESAs and HIF-PHIs
Ferritin and transferrin saturation should not be interpreted in isolation, particularly in inflammatory states. Route of iron administration should reflect CKD stage, dialysis status, previous response, tolerability and adherence. ESAs continue to have an important role, particularly in dialysis populations and selected non-dialysis patients, but contemporary care is individualized rather than focused on normalization of hemoglobin.
HIF-prolyl hydroxylase inhibitors add an evolving option. Their place in practice depends on patient characteristics, regulatory status, availability and long-term safety evidence.
Key clinical takeaways
- Begin with systematic evaluation and reversible causes.
- Iron status, ESA decisions and transfusion avoidance remain central.
- HIF-PHIs are an evolving therapeutic option requiring individualized assessment.
References
- KDIGO. 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease. Kidney International. 2026.
- KDIGO official guideline page.